CPC Scientific, a premier peptide and oligonucleotide-focused CRDMO and a wholly owned subsidiary of Medtide Inc. (HKEX: 3880.HK), today announced that its Hangzhou-based CGMP manufacturing facility, Chinese Peptide Company, has successfully completed the Drug Master File (DMF) filing for its self-developed Tirzepatide active pharmaceutical ingredient (API) with the U.S. Food and Drug Administration (FDA) under DMF number 043979.
Dive into Joseph Denby's presentation at NextGen Biomed 2026, where he shares a case study on delivering sustainable, efficient peptide manufacturing on scale through our advanced SPPS process optimizations.
CPC Scientific had a fantastic time connecting with partners this year at DCAT Week 2026. See our standout highlights from New York, featuring generic API scale-up, the 98th DCAT Annual Dinner, and more...
Catch CPC Scientific's key highlights from NextGen Biomed 2026, where we showcased how our advanced process design is accelerating production timelines and cost efficiency for greener TIDES manufacturing at scale...
Discover how CPC Scientific has earned the trust of top pharma and biotech companies across 50+ countries. See the numbers behind our track record as a leading peptide and oligonucleotide CDMO partner, including 300+ ongoing CMC development projects, 13 commercial GMP manufacturing programs, 25 years of global operations, 500+ employees, and more.
CPC Scientific is thrilled to return to CPHI Frankfurt 2025! Explore a tour of our booth as we recap key moments from Day 1 of CPHI Frankfurt, where we're highlighting our position as a global pioneer in peptide and oligonucleotide CDMO services...
In today’s biotech landscape, quality is essential. For therapeutics based on peptides or oligonucleotides, many of which treat complex or life-threatening conditions, GMP compliance is a foundational element of regulatory approval and patient trust.
Selecting the right partner can directly impact both speed-to-market and long-term commercial success, particularly for peptide and oligo programs. A CDMO addresses this by providing support across the drug development lifecycle.
At CPHI Frankfurt 2025, CPC Scientific will spotlight its position as a global leader in peptide and oligonucleotide CRDMO solutions. As the company’s largest event of the year, the showcase will emphasize innovation, regulatory excellence, and a proven track record of supporting partners worldwide. Visitors can connect with CPC Scientific’s leadership and scientific team at Booth 12.0F29 to explore new opportunities and collaborations.
CPC Scientific is back at Boulder Peptide Symposium 2025 as a Gold Sponsor! Discover key moments from the symposium and see how our team is pioneering innovations in large-scale synthesis as a leading peptide manufacturer...
